{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:50:49Z","timestamp":1773694249356,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A few studies on vaccination in patients with rheumatic diseases, including arthritis, connective tissue diseases, vasculitis, and psoriatic arthropathy (PsA), demonstrated reduced production of neutralizing antibodies to SARS-CoV-2 Spike RBD (receptor-binding domain contained in the N-terminal of the S1 globular head region) when compared to the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of our study was to observe whether different therapies for PsA [methotrexate, anti-TNF antibodies, soluble TNF receptor (etanercept) or IL-17 inhibitors] have a different impact on SARS-CoV-2 vaccination in a homogeneous population of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled 110 PsA patients in remission, assessed with Disease Activity in PSoriatic Arthritis (DAPSA). Of these: 63 were in treatment with anti-TNF-\u03b1 therapy (26 etanercept, 15 certolizumab, 5 golimumab, 17 adalimumab); 37 with anti-IL17 secukinumab; 10 with methotrexate. All patients underwent vaccination for SARS-CoV-2 with mRNA BNT162b2 vaccine. Assessment of absolute and percentage lymphocyte subsets and anti-SARS-CoV-2 Spike RBD IgG antibody value 3 weeks after the second vaccine dose were performed. In addition, the serum antibody levels of 96 healthy healthcare workers (HCW) were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean disease activity assessed with DAPSA score was 2.96 (SD = 0.60) with no significant differences between patients under different medications (<jats:italic>p<\/jats:italic> = 0.779). Median levels of neutralizing antibodies to SARS-CoV-2 Spike RBD were 928.00 binding antibody unit (BAU)\/mL [IQR 329.25, 1632.0]; 1068.00 BAU\/ml [IQR 475.00, 1632.00] in patients taking MTX, 846.00 BAU\/ml [IQR 125.00, 1632.00] in patients taking etanercept, 908.00 BAU\/mL [IQR 396.00, 1632.00] in patients taking anti-IL17 and 1148.00 BAU\/ml [IQR 327.00, 1632.00] in patients taking TNF-\u03b1 inhibitors, without statistically significant differences between these groups. Mean serum antibody level of HCW group was 1562.00 BAU\/ml [IQR 975.00, 1632.00], being significantly higher than in the patient group (<jats:italic>p<\/jats:italic> = 0.000816). Absolute and percentage count of lymphocyte subsets were not statistically different between the subgroups under different treatments and when compared with HCW.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>As for other rheumatic diseases on immunomodulatory treatment, our data showed a reduced humoral response in PsA patients compared to the control group. However, antibody response did not significantly differ between groups treated with different medications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.811829","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:27:46Z","timestamp":1646033266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?"],"prefix":"10.3389","volume":"9","author":[{"given":"Maurizio","family":"Benucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Lari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Biancamaria","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corr\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Quintarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Verdelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Li Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e000656","DOI":"10.1136\/rmdopen-2018-000656","article-title":"Distinguishing rheumatoid arthritis from psoriatic arthritis","volume":"4","author":"Merola","year":"2018","journal-title":"RMD Open."},{"key":"B3","first-page":"5","article-title":"A review for physician assistants and nurse practitioners on the considerations for diagnosing and treating psoriatic arthritis","volume-title":"Rheumatol Ther.","author":"Giannelli","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e000588","DOI":"10.1136\/rmdopen-2017-000588","article-title":"Real-world burden of comorbidities in US patients with psoriatic arthritis","volume":"3","author":"Shah","year":"2017","journal-title":"RMD Open."},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/NEJMc1704342","article-title":"Psoriatic arthritis","volume":"376","author":"Ciccia","year":"2017","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.rdc.2012.08.019","article-title":"Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention","volume":"38","author":"Winthrop","year":"2012","journal-title":"Rheum Dis Clin North Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/art.41301","article-title":"American College of Rheumatology Guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Boyarsky","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/art.41437","article-title":"American College of Rheumatology Guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : a prospective cohort study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2021.10.034","article-title":"Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: a nationwide study","volume":"86","author":"Joly","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jaad.2020.12.043","article-title":"Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study","volume":"84","author":"Mahmoudi","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e214302","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of age with SARS-CoV-2 antibody response","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw open."},{"key":"B28","doi-asserted-by":"publisher","first-page":"740249","DOI":"10.3389\/fimmu.2021.740249","article-title":"Immunosuppressivetherapies differently modulate humoral- and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients","volume":"12","author":"Picchianti-Diamanti","year":"2021","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.42030.","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic disease: a systematic literature review and meta-analysis","author":"Conway","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8040728","article-title":"The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments","volume":"8","author":"Gisondi","year":"2020","journal-title":"Vaccines."},{"key":"B31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14712598.2021.1853698","article-title":"Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study","volume":"21","author":"Talamonti","year":"2021","journal-title":"Expert Opin Biol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaci.2020.10.032","article-title":"Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience","volume":"147","author":"Gisondi","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"105095","DOI":"10.1016\/j.jbspin.2020.105095","article-title":"COVID-19 in French patients with chronic inflammatory rheumatic diseases: Clinical features, risk factors and treatment adherence","volume":"88","author":"Costantino","year":"2021","journal-title":"Joint Bone Spine."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00296-020-04676-4","article-title":"Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes","volume":"40","author":"Montero","year":"2020","journal-title":"Rheumatol Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2020-218054","article-title":"Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases","volume":"79","author":"Nu\u00f1o","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0233147","DOI":"10.1371\/journal.pone.0233147","article-title":"Prevalence, severity and mortality associated with COPD and Smoking in patients with COVID-19: a rapid systematic review and meta-analysis","volume":"15","author":"Alqahtani","year":"2020","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1003374","DOI":"10.1371\/journal.pmed.1003374","article-title":"Rapid epidemiological analysis of comorbidities and treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study","volume":"17","author":"McKeigue","year":"2020","journal-title":"PLoS Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijid.2020.07.029","article-title":"Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis","volume":"99","author":"Zhou","year":"2020","journal-title":"Int J Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.811829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:27:50Z","timestamp":1646033270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.811829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":41,"alternative-id":["10.3389\/fmed.2022.811829"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.811829","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"article-number":"811829"}}